Amgen has announced the groundbreaking of its newest biomanufacturing facility in North Carolina.
Amgen announced on March 7, 2022 the groundbreaking of its new biomanufacturing facility, located in Holly Springs, NC, that is expected to be operational by 2025. The facility will support the growing demand for medicines that treat serious illnesses such as cancer and heart disease. The new facility will produce a wide range of medicines, utilizing new technologies to maximize efficiency and quality.
"For over four decades, Amgen has been an innovative leader in the manufacturing of complex biologics. Our commitment to continuous improvement and our significant investments in new technologies have enabled us to further accomplish our mission to serve patients while science rapidly evolves," said Robert A. Bradway, chairman and CEO of Amgen, in a press release. "We are delighted to be building our newest facility in North Carolina, a major hub for biopharmaceutical innovation."
The facility will be environmentally conscious, focusing on reducing water usage and waste. Amgen is also focused on increasing diversity in the workplace through the OneTen Coalition, which it is a founding member of. The Coalition’s goal is to change the employment paradigm for black people in the United States. “To achieve this goal, Amgen will work with businesses, educational institutions, and training partners to better develop, retain, and advance diverse talent, focusing on Black Americans without four-year college degrees,” the company said in the press release.
Source: Amgen
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.